Literature DB >> 34671868

Adverse Effects of Immunosuppression: Infections.

Guy Handley1, Jonathan Hand2.   

Abstract

Immunosuppressive therapies are currently indicated for a wide range of diseases. As new agents emerge and indications evolve the landscape grows increasingly complex. Therapies can target pathologic immune system over-activation in rheumatologic or autoimmune disease, or conditioning and graft versus host disease (GVHD) prophylactic regimens may eliminate or inhibit host immune function to improve graft survival and risk of complication in solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). With immunosuppressive therapy, infections occur. Complex disease states, host factors, and concomitant therapies contribute to a "net state" of immunosuppression that must be considered and may confound perceived increased infection risks in patients receiving treatment.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Immunocompromised hosts; Immunosuppression; Opportunistic infection; Transplant and immunocompromised infectious diseases

Mesh:

Year:  2022        PMID: 34671868     DOI: 10.1007/164_2021_550

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  178 in total

1.  Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod.

Authors:  Lutz Achtnichts; Otilia Obreja; Anna Conen; Christoph A Fux; Krassen Nedeltchev
Journal:  JAMA Neurol       Date:  2015-10       Impact factor: 18.302

Review 2.  Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection.

Authors:  Anthony C Allison; Elsie M Eugui
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

3.  Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?

Authors:  N Basic-Jukic; P Kes; L J Bubic-Filipi; Z Puretic; B Brunetta; J Pasini
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

4.  Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.

Authors:  A B Adams; J Goldstein; C Garrett; R Zhang; R E Patzer; K A Newell; N A Turgeon; A S Chami; A Guasch; A D Kirk; S O Pastan; T C Pearson; C P Larsen
Journal:  Am J Transplant       Date:  2017-07-03       Impact factor: 8.086

5.  Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Authors:  Ann M Arvin; Jerry S Wolinsky; Ludwig Kappos; Michele I Morris; Anthony T Reder; Carlo Tornatore; Anne Gershon; Michael Gershon; Myron J Levin; Mauritz Bezuidenhoudt; Norman Putzki
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

6.  Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab.

Authors:  David Ansari; Lars H Lund; Josef Stehlik; Bodil Andersson; Peter Höglund; Leah Edwards; Johan Nilsson
Journal:  J Heart Lung Transplant       Date:  2015-05-02       Impact factor: 10.247

Review 7.  Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.

Authors:  Ella J Ariza-Heredia; Lior Nesher; Roy F Chemaly
Journal:  Cancer Lett       Date:  2013-09-13       Impact factor: 8.679

Review 8.  Classifying PML risk with disease modifying therapies.

Authors:  Joseph R Berger
Journal:  Mult Scler Relat Disord       Date:  2017-01-06       Impact factor: 4.339

Review 9.  Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.

Authors:  Yasuyuki Arai; Tomoyasu Jo; Hiroyuki Matsui; Tadakazu Kondo; Akifumi Takaori-Kondo
Journal:  Leuk Lymphoma       Date:  2016-12-12

10.  Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.

Authors:  Sara Barmettler; Mei-Sing Ong; Jocelyn R Farmer; Hyon Choi; Jolan Walter
Journal:  JAMA Netw Open       Date:  2018-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.